The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights.
Coutinho AE, Chapman KE. · 2011
Read The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. by Coutinho AE, Chapman KE. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3047790.txt.
Introduction
Coutinho and Chapman reviewed in 2011 how glucocorticoid drugs calm inflammation and suppress the immune system, and why their long term use is a bargain with harm. Since the nineteen forties these drugs have been among the most effective treatments for inflammatory and autoimmune disease. Their costs include bone thinning, high blood pressure, disturbed blood fats, and raised diabetes risk.
Drug hunters have long tried to split the benefits from the harms, with limited success so far. The review gathers recent, sometimes surprising findings on how the drugs actually work inside cells. One local enzyme that boosts or cuts the drugs' strength inside tissues gets close attention. Better maps of these pathways, the authors argue, are the route to safer versions. The paper is a status report for researchers chasing that split.
Catalog record
| CREATOR | Coutinho AE, Chapman KE. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 107 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights By Agnes E Coutinho, Karen E Chapman Published in: Molecular and Cellular Endocrinology DOI: 10.1016/j.mce.2010.04.005 ABSTRACT Abstract Since the discovery of glucocorticoids in the 1940s and the recognition of their anti-inflammatory effects, they have been amongst the most widely used and effective treatments to control inflammatory and autoimmune diseases. However, their clinical efficacy is compromised by the metabolic effects of long-term treatment, which include osteoporosis, hypertension, dyslipidaemia and insulin resistance/type 2 diabetes mellitus. In recent years, a great deal of effort has been invested in identifying compounds that separate the beneficial anti-inflammatory effects from the adverse metabolic effects of glucocorticoids, with limited effect. It is clear that for these efforts to be effective, a greater understanding is required of the mechanisms by which glucocorticoids exert their anti-inflammatory and immunosuppressive actions. Recent research is shedding new light on some of these mechanisms and has produced some surprising new findings. Some of these recent developments are reviewed here. Keywords: Glucocorticoid, Inflammation, 11β-Hydroxysteroid dehydrogenase INTRODUCTION Natural and synthetic glucocorticoids remain at the forefront of anti-inflammatory and immunosuppressive therapies. They are widely used to treat both acute and chronic inflammations, including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis and eczema, as well as being used in treatment of certain leukaemias and in immunosuppressive regimes following organ transplant. At any one time, an estimated ∼1% of the total adult population of the UK receives oral glucocorticoid therapy (van Staa et al., 2000). However, long-term use of oral glucocorticoids is associated with serious side effects, including osteoporosis, metabolic disease and increased risk of cardiovascular disease (Wei et al., 2004; Souverein et al., 2004; de Vries et al., 2007; Vegiopoulos and Herzig, 2007)—in themselves, somewhat paradoxically, inflammatory conditions. Over the 60 years since the discovery of glucocorticoids, much has been learnt of the molecular mechanisms by which they act (recently reviewed; Perretti and Ahluwalia (2000), Necela and Cidlowski (2004), Yeager et al. (2004), Rhen and Cidlowski (2005), Smoak and Cidlowski (2004), Tuckermann et al. (2005), Kleiman and Tuckermann (2007), Newton and Holden (2007) and De Bosscher and Haegeman (2009)), with milestones being the characterisation of the glucocorticoid receptor (GR) as a DNA binding protein that regulates transcription initiation (reviewed, Yamamoto (1985)), the cloning of GR (Hollenberg et al., 1985; Miesfeld et al., 1986) and the discovery that many of the immunosuppressive actions of glucocorticoids are mediated by interference with signalling by the key inflammatory transcriptional regulators; NF-κB and AP-1 (Jonat et al., 1990; Yangyen et al., 1990; Heck et al., 1994) (reviewed, McKay and Cidlowski (1999)). However, much also remains unknown and the past few years have provided crucial mechanistic insights into the dynamic nature of GR interactions with DNA and higher order chromatin structures, into the subtleties of ligand effects on GR function, the regulation of endogenous ligand access to GR, glucocorticoid effects on leukocyte differentiation and function and the mechanistic basis for some of the repressive actions of glucocorticoids, critical for their anti-inflammatory effects. INFLAMMATION AND ITS RESOLUTION The host inflammatory response is a primary defence mechanism engaged immediately following injury or infection which is necessary to restore homeostasis following successful elimination of the injurious agent, ultimately leading to resolution and tissue repair. Although categorically distinct, the innate (the relatively non-specific immediate host defence system that provides a rapid reaction to infection and tissue damage) and adaptive (the more slowly acquired, highly antigen-specific response) immune systems interact and often overlap during an inflammatory response. Indeed, although acute inflammation is largely mediated by the innate immune system, the adaptive immune system often plays a major role in chronic inflammatory disease, with dysregulated lymphocyte responses. Inflammation is initiated at the site of injury by resident cells, particularly mast cells and resident macrophages, which release pro-inflammatory mediators including bioactive amines, lipid mediators and cytokines—typically TNF-α and IL-1. These cause vasodilation, increased capillary permeability (humoral response) and leukocyte emigration into injured tissues (cellular response), resulting in the hallmark pain, heat, redness and swelling of inflammation as well as generating a chemotactic gradient to guide and activate recruited cells to the site of injury. Although specific characteristics depend on the immune exposure (e.g. irritant vs pathogen), the recruitment process and activation of inflammatory cells are common. Activated granulocytes, crucial to contain microbial infection, are rapidly attracted to the inflamed site, followed by monocyte emigration from blood vessels and subsequent maturation into macrophages. Once at the inflamed site, neutrophils undergo constitutive apoptosis, functionally isolating them from the inflammatory environment by loss of stimulated chemotaxis, phagocytosis, degranulation and respiratory burst (Haslett et al., 1991; Whyte et al., 1993), whilst at the same time, facilitating safe removal of their potentially histotoxic contents by macrophages (Savill et al., 2002). Foreign antigens are taken up by antigen presenting cells; particularly dendritic cells, but also macrophages, that then migrate to draining lymph nodes where they instruct the adaptive immune system (T and B lymphocytes), shaping the subsequent immune response. As the inflammatory response progresses and evolves, mononuclear cells predominate and resolution normally ensues. Successful resolution of acute inflammation is an active and highly regulated process and dependent on mechanisms engaged early in the inflammatory response that programme the trajectory and form of the subsequent resolution (reviewed Savill et al. (2002), Gilroy (2004) and Serhan and Savill (2005)). Persistence of the initiating stimulus invariably leads to chronic inflammation, with the typical dysregulation between destructive inflammatory and excessive healing responses seen in diseases such as arthritis, atherosclerosis and asthma. GLUCOCORTICOIDS AND INFLAMMATION Glucocorticoids inhibit many of the initial events in an inflammatory response. They also promote the resolution of inflammation although the mechanisms by which they do so have received less attention than those associated with suppression of the initial response. Acutely, glucocorticoids inhibit the vasodilation and increased vascular permeability that occurs following inflammatory insult and they decrease leukocyte emigration into inflamed sites, effects that require new protein synthesis (reviewed Perretti and Ahluwalia (2000)). They also alter leukocyte distribution/trafficking (McEwen et al., 1997), death/survival (McEwen et al., 1997; Ashwell et al., 2000; Planey and Litwack, 2000; Herold et al., 2006; McColl et al., 2007) and, importantly, alter cellular differentiation programmes, thus shaping the subsequent response (see below). Most of the anti-inflammatory and immunosuppressive actions of glucocorticoids are attributable either directly or indirectly to the transcriptional effects of GR agonism which alters transcription of numerous genes in leukocytes, both up and down (Ashwell et al., 2000; McEwen et al., 1997). Although expression of mineralocorticoid receptor (MR), which binds glucocorticoids with high affinity in the absence of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2; see below), has been reported in immune cells (Miller et al., 1990; Barish et al., 2005; Lim et al., 2007) (which do not normally express 11β-HSD2 Gilmour et al. (2006), Lim et al. (2007)), it appears of little consequence to the anti-inflammatory effects of glucocorticoids, and may even have pro-inflammatory effects (Lim et al., 2007; Harizi et al., 2008). It should also be noted that some anti-inflammatory effects of glucocorticoids are apparent within minutes and a number are independent of the transcriptional effects of GR (see for example Croxtall et al. (2002), Limbourg et al. (2002) and Stellato (2004)). Notably, glucocorticoids repress transcription of many